Merck's Capvaxive gears up to challenge Pfizer's dominant Prevnar with CDC panel backing
Fierce Pharma
JUNE 28, 2024
After scoring approval as the world’s first pneumococcal disease vaccine made specifically for adults earlier this month, Merck’s Capvaxive passed the next test in its bid to take on Pfizer an | The recommendation sets up Merck's new pneumococcal disease vaccine to potentially capture some of Pfizer's market share.
Let's personalize your content